| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-006 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次日常关联交易预计已经独立董事专门会议、董事会审议通过，无 需提交股东会审议。 2026 年度预计的日常关联交易是基于宁波美诺华药业股份有限公司（以 下简称"公司"）及子公司正常生产经营需要所发生的，有利于公司业务的开展， 交易定价客观、公正、合理，不会对公司的财务状况、经营成果产生不利影响， 不存在损害公司及全体股东利益的情形，不会对公司的独立性构成影响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、2026年1月16日，公司召开第五届董事会第二十三次会议审议通过了《关 于2026年度日常关联交易预计的议案》，关联董事姚成志先生予以回避表决，该 议案获出席会议的非关联董事一致表决通过。 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-005 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 第五届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 宁波美诺华药业股份有限公司（以下简称"公司"）于 2026 年 1 月 9 日通过 书面及电子邮件等方式向全体董事发出通知，提议召开第五届董事会第二十三次 会议，原定审议《关于 2026 年度日常关联交易预计的议案》。截至第五届董事会 第二十三次会议召开日，公司股票已满足"在任意连续三十个交易日中至少有十 五个交易日收盘价低于当期转股价格 25.68 元/股的 90%（即 23.11 元/股）"的 条件，触发"美诺转债"转股价格向下修正条款，故全体董事一致同意本次会议 临时增加《关于向下修正"美诺转债"转股价格的议案》。本次会议于 2026 年 1 月 16 日在公司会议室以现场与通讯相结合的方式召开。本次会议 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Lianxi Guo tablets, enhancing its market competitiveness and product pipeline [1][4]. Group 1: Drug Information - Drug Name: Lianxi Guo tablets - Dosage Form: Tablets - Specifications: 0.5mg, 1mg, 2.5mg - Application Matter: Drug registration (domestic production) - Registration Category: Chemical drug category 4 - Acceptance Numbers: CYHS2402749, CYHS2402750, CYHS2402751 - Drug Approval Numbers: National Drug Approval H20263049, H20263050, H20263051 - Validity of Drug Approval Numbers: Until January 4, 2031 - Marketing Authorization Holder: Ningbo Meinuo Hua Tiankang Pharmaceutical Co., Ltd. - Manufacturing Enterprise: Ningbo Meinuo Hua Tiankang Pharmaceutical Co., Ltd. [4] Group 2: Drug Mechanism and Indications - Indications: Suitable for chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) - Mechanism of Action: Lianxi Guo is a soluble guanylate cyclase (sGC) agonist that enhances the sensitivity of sGC to endogenous NO and directly stimulates sGC through different binding sites, increasing cGMP production and causing vasodilation [2]. Group 3: Market Context - As of the announcement date, three domestic companies have been approved for Lianxi Guo tablets, including Qilu Pharmaceutical Co., Ltd., Jiangsu Huayang Pharmaceutical Co., Ltd., and Ningbo Meinuo Hua Tiankang Pharmaceutical Co., Ltd. [3] - The global sales of Lianxi Guo tablets in 2024 are projected to be approximately $49.42 million, with sales in China estimated at $1.04 million [3].

Core Viewpoint - The announcement highlights that Ningbo Meinuo Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., has received the drug registration certificate for Lianxiqiao tablets from the National Medical Products Administration, allowing for domestic production and sales of the drug [1][4]. Drug Information - Drug Name: Lianxiqiao Tablets [3] - Dosage Form: Tablets [3] - Specifications: 0.5mg, 1mg, 2.5mg [3] - Registration Classification: Chemical Drug Class 4 [3] - Approval Number: National Drug Approval Numbers H20263049, H20263050, H20263051 [1][3] - Validity of Approval: Until January 4, 2031 [3] Drug Mechanism and Indications - Indications: Suitable for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH) [2] - Mechanism: Lianxiqiao acts as a soluble guanylate cyclase (sGC) agonist, enhancing the sensitivity of sGC to endogenous NO and directly stimulating sGC through different binding sites, leading to increased cGMP production and vasodilation [2]. Market Context - As of the announcement date, three domestic companies have been approved for Lianxiqiao tablets, including Qilu Pharmaceutical Co., Ltd. and Jiangsu Huayang Pharmaceutical Co., Ltd. [4] - Global sales of Lianxiqiao tablets in 2024 are projected to be approximately $49.42 million, with sales in China estimated at $1.04 million [4]. Impact on Company - The approval of Lianxiqiao tablets enhances the company's market competitiveness and enriches its product pipeline, contributing positively to its operational development [4].

Core Viewpoint - Meihua (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Liosiguat tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option in the market [1] Group 1 - The drug Liosiguat is indicated for the treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH) [1]

Core Viewpoint - Meihua (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Liosiguat tablets from the National Medical Products Administration, indicating a significant regulatory approval for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) [1] Group 1 - The drug Liosiguat is approved for the treatment of CTEPH and PAH, which are serious conditions affecting pulmonary circulation [1]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-004 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于全资子公司获得利奥西呱片 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的利奥西呱片《药品注册证书》，现将相关 情况公告如下： 一、药品相关信息 1、药品名称：利奥西呱片 2、剂型：片剂 3、规格：0.5mg，1mg，2.5mg 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 4 类 6、受理号：CYHS2402749, CYHS2402750，CYHS2402751 7、药品批准文号：国药准字 H20263049, 国药准字 H20263050，国药准字 H20263051 8、药品批准文号有效期：至 20 ...

Group 1 - The core point of the article is that Meinuohua's subsidiary has received approval from the National Medical Products Administration for the registration of Liosiguap tablets, enhancing the company's market competitiveness and product pipeline [1][3]. Group 2 - The drug is indicated for chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) [2]. - Liosiguap acts as a soluble guanylate cyclase (sGC) agonist, which plays a crucial role in the pulmonary circulation system by catalyzing the synthesis of cyclic guanosine monophosphate (cGMP) [2]. - The company has invested approximately RMB 6.8671 million in the research and development of Liosiguap tablets as of the announcement date [2].

Core Viewpoint - Meheco's wholly-owned subsidiary, Meheco Tiankang, has received the drug registration certificate for Liosiguat tablets from the National Medical Products Administration, enhancing the company's market competitiveness in the treatment of chronic thromboembolic pulmonary hypertension and arterial pulmonary hypertension [1] Group 1: Company Developments - The drug Liosiguat acts as a soluble guanylate cyclase (sGC) agonist, expanding blood vessels through the NO-sGC-cGMP pathway [1] - Meheco Tiankang is now qualified to produce and sell Liosiguat tablets in the domestic market following the approval [1] - The approval marks a significant milestone for Meheco Tiankang, as it joins two other approved companies, Qilu Pharmaceutical and Jiangsu Huayang Pharmaceutical, in the domestic market [1] Group 2: Market Potential - The global sales forecast for Liosiguat tablets in 2024 is approximately $494.16 million, with expected sales in China around $10.38 million [1] - The approval of Liosiguat tablets is expected to enhance the company's product competitiveness in a growing market [1] Group 3: Future Considerations - Future sales of Liosiguat tablets may be influenced by various uncertainties, including policy changes, market demand, and competition from similar drugs [1]

| | | 宁波美诺华药业股份有限公司 关于"美诺转债"预计满足转股价格向下修正条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转换公司债券基本情况 （一）可转换公司债券发行上市概况 经中国证券监督管理委员会《关于核准宁波美诺华药业股份有限公司公开发 行可转换公司债券的批复》（证监许可[2020]2377 号）核准，2021 年 1 月 14 日， 宁波美诺华药业股份有限公司（以下简称"公司"）公开发行 52,000 万元可转换 公司债券，共发行 520 万张，每张面值 100 元，期限 6 年。2021 年 2 月 4 日起， 上述可转换公司债券在上海证券交易所挂牌交易，转债简称"美诺转债"，转债 代码"113618"。 "美诺转债"存续的起止日期为 2021 年 1 月 14 日至 2027 年 1 月 13 日，转 股期起止日期为 2021 年 7 月 20 日至 2027 年 1 月 13 日，初始转股价格为 37.47 元/股。 （二）可转换公司债券转股价格历次调整情况 二、可转换公司债券转股 ...